Clinical Trials Sponsored by Colotech A/S

Total 2522 results

H. Lundbeck A/S

Completed

A Study Investigating Tablet Formulations of Lu AF11167 in Healthy Subjects

Healthy

United Kingdom
H. Lundbeck A/S

Completed

Study With Vortioxetine on Emotional Functioning in Patients With Depression (COMPLETE)

Major Depressive Disorder

France, Italy, Lithuania, Spain
Novo Nordisk A/S

Completed

A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD) (DUAL™ II China)

Diabetes Mellitus, Type 2 | Diabetes

Hong Kong, China
Novo Nordisk A/S

Completed

A Research Study Looking at How Faster Aspart Injected in Double Concentration Works in the Body of People With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart in Healthy Chinese Subjects

Healthy

China
Novo Nordisk A/S

Completed

Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A (alleviate 1)

Congenital Bleeding Disorder | Haemophilia A

United States, Austria, Serbia, Germany, Japan, France
H. Lundbeck A/S

Completed

A Positron Emission Tomography (PET) Study to Examine the Brain Binding Properties of a Novel Radioactive Compound [11C]-PXT012253 in Healthy Subjects

Parkinson Disease

Sweden
Novo Nordisk A/S

Completed

Research Study to Investigate How a Study Medicine (NNC9204- 1177) Affects Blood Levels of Other Medicines in Healthy People

Obesity | Overweight | Healthy Volunteers

United States
Novo Nordisk A/S

Completed

RESILIENT: A Research Study, Looking at How Ryzodeg® Works in People With Type 2 Diabetes in Local Clinical Practice in Japan (RESILIENT)

Diabetes Mellitus, Type 2

Japan
RSP Systems A/S

Completed

Database and Calibration of a Non-invasive Glucose Monitoring Device

Diabetes

Denmark
H. Lundbeck A/S

Completed

Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia (DayBreak)

Schizophrenia

Estonia, Mexico, Poland, Serbia, Ukraine, United States, Bulgaria, Canada, Czechia, Finland, Romania, Russian Federation, Slovakia, Spain
Novo Nordisk A/S

Completed

A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia (eTHINK)

Haemophilia A | Haemophilia B

United States
H. Lundbeck A/S

Terminated

A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD)

Alzheimer's Disease

Finland, Sweden
Novo Nordisk A/S

Completed

An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry

Diabetes Mellitus, Type 2 | Diabetes Mellitus | Diabetes Mellitus, Type 1

Israel, United Kingdom, France, Netherlands, Spain, Finland, Malaysia, Norway, Italy, Germany, Poland, Romania, Portugal, Ireland, Croatia, Greece
Novo Nordisk A/S

Completed

French National Registry of Adults With Growth Hormone Deficiency Treated With Somatropin

Growth Hormone Disorder | Adult Growth Hormone Deficiency

France
H. Lundbeck A/S

Completed

What the Body Does to Foliglurax in Healthy Volunteers (Foliglurax)

Healthy

United Kingdom
Novo Nordisk A/S

Completed

Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ryzodeg®

Diabetes

Japan
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. (SUSTAIN 7)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, India, Slovakia, Spain, United Kingdom, Finland, Ireland, Germany, Greece, Puerto Rico, Romania, Bulgaria, Latvia, Hong Kong, Lithuania, Portugal
Novo Nordisk A/S

Completed

Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes (SUSTAIN 10)

Diabetes Mellitus, Type 2 | Diabetes

Italy, Spain, United Kingdom, France, Sweden, Finland, Poland, Slovenia, Hungary, Germany, Bulgaria, Czechia
H. Lundbeck A/S

Completed

Study Evaluating the Effect of Multiple Doses of Itraconazole on the Drug Lu AF35700 in Healthy Young Men and Women

Cytochrome P450 Interaction

United Kingdom, United States
H. Lundbeck A/S

Completed

Single Dose of Lu AF28996 to Healthy Young Men

Healthy

Netherlands
Novo Nordisk A/S

Completed

Validation of a Questionnaire That Identifies the Reasons for Non-adherence to Existing Growth Hormone Therapy

Growth Hormone Deficiency in Children

Germany
Novo Nordisk A/S

Completed

A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese

Obesity and Overweight

United States
H. Lundbeck A/S

Completed

Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression

Major Depressive Disorder

Bulgaria, Estonia, Latvia
Novo Nordisk A/S

Completed

A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide

Diabetes Mellitus, Type 2 | Diabetes

India, Italy, Spain, Austria, Finland, Hungary, Turkey, France, United Kingdom, Switzerland, Bulgaria, Germany, South Africa, Former Serbia and Montenegro
Novo Nordisk A/S

Completed

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER®)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, India, Israel, Italy, Mexico, Puerto Rico, Russian Federation, Spain, United Kingdom, Denmark, Sweden, Netherlands, Austria, Belgium, Taiwan, Finland, Norway, Serbia, South Africa, Turkey, Canada, France, Germany, Korea, Republic of and more
RSP Systems A/S

Completed

Ex Vivo Evaluation of Laser Induced Thermal Tissue Damage

Gastric Bypass Surgery

Denmark
Novo Nordisk A/S

Completed

A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity

Obesity | Overweight

United States
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (SUSTAIN™ 2)

Diabetes Mellitus, Type 2 | Diabetes

India, Japan, Russian Federation, Spain, Sweden, Argentina, Hungary, Norway, South Africa, Turkey, Bulgaria, Romania, Thailand, Portugal, Hong Kong, Mexico, Ukraine, Czechia
Novo Nordisk A/S

Completed

Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes (onset® 1)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, Finland, Belgium, Hungary, United Kingdom, Germany, Canada, Czechia
Novo Nordisk A/S

Completed

Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes (onset® 3)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Mexico, Argentina, Slovenia, Romania
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes (SUSTAIN™ 5)

Diabetes Mellitus, Type 2 | Diabetes

United States, Slovakia, Japan, Puerto Rico, Serbia, Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus

Diabetes | Diabetes Mellitus, Type 1

United States, India, Russian Federation, Belgium, Spain, Israel, Croatia, Serbia, North Macedonia, South Africa, Slovenia, Brazil, Poland, Canada, Czechia
Novo Nordisk A/S

Completed

Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin

Diabetes | Type 2 Diabetes Mellitus

Taiwan, Turkey, India, Algeria, Hong Kong, China, Ukraine
Novo Nordisk A/S

Completed

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes (onset®7)

Diabetes | Diabetes Mellitus, Type 1

Germany, United States, India, Israel, Italy, Russian Federation, Japan, Finland, Serbia, Turkey, Bulgaria, Estonia, Czechia, Lithuania, Ukraine, Poland, Latvia, Puerto Rico
Novo Nordisk A/S

Completed

Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function.

Growth Hormone Disorder | Growth Hormone Deficiency in Children | Adult Growth Hormone Deficiency

Slovakia
Novo Nordisk A/S

Completed

Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes (BOOST)

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

A Research Study of How Faster-acting Insulin Aspart Moves Into, Through, and Out of the Body and How it Works in the Body When Given Through an Insulin Pump to People With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Dermtreat
Larix A/S

Completed

The Comfort and Adherence of Rivelin® Plain Patches in Vulva Lichen Sclerosus Patients

Vulvar Lichen Sclerosus

Denmark
H. Lundbeck A/S

Completed

Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer

Alzheimer Dementia (AD)

China
Novo Nordisk A/S

Completed

Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes (onset® 2)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, India, Israel, Russian Federation, Slovakia, Canada, Serbia, United Kingdom, Puerto Rico
Ascendis Pharma A/S

Terminated

A Safety, Tolerability and Pharmacokinetics Study of TransCon Treprostinil in Healthy Adult Male Volunteers

Healthy Volunteers
Novo Nordisk A/S

Completed

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
RSP Systems A/S

Completed

Comparative Study Between Two Models of a Non-invasive Glucose Monitoring Device

Type1diabetes

Denmark
Novo Nordisk A/S

Completed

Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes (Lead-Ph)

Diabetes Mellitus, Type 2 | Diabetes

Philippines
Novo Nordisk A/S

Completed

Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin (LIRA-SWITCH™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Israel, Canada, Hungary, India, Spain, Puerto Rico
UNEEG Medical A/S

Completed

Evaluation of Hypo-Safe Hypoglycaemia Alarm Device - the Pilot 2 Study - Healthy Subjects

Healthy

Denmark

3

Subscribe